Infrared Fluorescent Imaging as a Potent Tool for In Vitro, Ex Vivo and In Vivo Models of Visceral Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 9, Issue 3, 2015, Pages

  Calvo Álvarez, Estefanía ^a   Stamatakis, Kostantinos ^b   Punzón, Carmen ^c   Álvarez Velilla, Raquel ^a   Tejería, Ana ^a   Escudero Martínez, José Miguel ^a   Pérez Pertejo, Yolanda ^a   Fresno, Manuel ^b   Balaña Fouce, Rafael ^a   Reguera, Rosa M ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Parque Cientifico de Madrid ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CARBACHOL; COMBRETASTATIN; DIMETHYL SULFOXIDE; HEAT SHOCK PROTEIN 70; HYGROMYCIN B; INDENOISOQUINOLINE; ISOQUINOLINE DERIVATIVE; OLIGONUCLEOTIDE; RED FLUORESCENT PROTEIN; RNA 18S; UNCLASSIFIED DRUG;

A2 GENE; AMASTIN GENE; ANIMAL CELL; ARTICLE; CC50; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ELECTROPORATION; EXPLANT; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GENE; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IC50; INFRARED FLUORESCENT IMAGING; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROCESS OPTIMIZATION; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SCREENING; INFRARED RADIATION; LEISHMANIASIS, VISCERAL; PROCEDURES; REPORTER GENE;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFRARED RAYS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; OPTICAL IMAGING;

EID: 84928798956     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003666     Document Type: Article

References (47)

1. WHO (2010) Working to overcome the global impact of neglected tropical diseases. Geneva: World Health Organization. 21438440
2. Hotez PJ, (2008) Forgotten people, forgotten diseases: The neglected tropical diseases and their impact on global health and development. Washington, DC: American Society for Microbiology.
3. Hayden EC, (2014) Projects set to tackle neglected diseases. Nature 505: 142. doi: 10.1038/505142a 24402261
4. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007). Control of neglected tropical diseases. N Engl J Med 357: 1018–1027. 17804846
5. Sundar S, Singh A, Singh OP, (2014) Strategies to overcome antileishmanial drugs unresponsiveness. J Trop Med 2014: 646932. doi: 10.1155/2014/646932 24876851
6. Mohapatra S, (2014) Drug resistance in leishmaniasis: Newer developments. Trop Parasitol 4: 4–9. doi: 10.4103/2229-5070.129142 24754020
7. Evans KJ, Kedzierski L, (2012) Development of vaccines against visceral leishmaniasis. J Trop Med 2012: 892817. doi: 10.1155/2012/892817 21912561
8. Reguera RM, Calvo-Álvarez E, Álvarez-Velilla R, Balaña-Fouce R, (2014) Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf? Int J Parasitol Drugs Drug Resist 4: 355–357. doi: 10.1016/j.ijpddr.2014.05.001 25516847
9. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL, (2012) Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2: 11–19. doi: 10.1016/j.ijpddr.2012.01.003 24533267
10. Siqueira-Neto JL, Moon S, Jang J, Yang G, Lee C, et al. (2012) An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl Trop Dis 6: e1671. doi: 10.1371/journal.pntd.0001671 22720099
11. Jain SK, Sahu R, Walker LA, Tekwani BL, . (2012) A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp. pii: 4054.
12. Calvo-Álvarez E, Alvarez-Velilla R, Fernández-Prada C, Balaña-Fouce R, Reguera RM, (2014) Trypanosomatids see the light: recent advances in bioimaging research. Drug Discov Today pii: S1359-6446(14)00378–X.
13. Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC, (2005) Bioluminescence imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between strains. Infect Immun 73: 695–702. 15664907
14. Franke-Fayard B, Waters AP, Janse CJ, (2006) Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. Nat Protoc 1: 476–485. 17406270
15. Claes F, Vodnala SK, van Reet N, Boucher N, Lunden-Miguel H, et al. (2009) Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination, which may hamper drug efficacy in sleeping sickness. PLoS Negl Trop Dis 3: e486. doi: 10.1371/journal.pntd.0000486 19621071
16. Dube A, Gupta R, Singh N, (2009) Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 25: 432–439. doi: 10.1016/j.pt.2009.06.006 19720564
17. Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A, (2009) Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother 64: 370–374. doi: 10.1093/jac/dkp206 19525291
18. Calvo-Álvarez E, Guerrero NA, Alvarez-Velilla R, Prada CF, Requena JM, et al. (2012) Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis. PLoS Negl Trop Dis 6: e1927. doi: 10.1371/journal.pntd.0001927 23209866
19. Rocha MN, Corrêa CM, Melo MN, Beverley SM, Martins-Filho OA, et al. (2013) An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein. Diagn Microbiol Infect Dis 75: 282–291. doi: 10.1016/j.diagmicrobio.2012.11.018 23312610
20. Shcherbo D, Merzlyak EM, Chepurnykh TV, Fradkov AF, Ermakova GV, et al. (2007) Bright far-red fluorescent protein for whole-body imaging. Nat Methods 4: 741–746. 17721542
21. Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, et al. (2009) Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 324: 804–807. doi: 10.1126/science.1168683 19423828
22. Filonov GS, Piatkevich KD, Ting LM, Zhang J, Kim K, et al. (2012) Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol 29: 757–761. doi: 10.1016/j.nbt.2012.03.002 22433081
23. Charest H, Zhang WW, Matlashewski G, (1996) The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region. J Biol Chem 271: 17081–17090. 8663340
24. Boucher N, Wu Y, Dumas C, Dube M, Sereno D, et al. (2002) A common mechanism of stage-regulated gene expression in Leishmania mediated by a conserved 3'-untranslated region element. J Biol Chem 277: 19511–19520. 11912202
25. Folgueira C, Requena JM, (2007) Pitfalls of the CAT reporter gene for analyzing translational regulation in Leishmania. Parasitol Res 101: 1449–1452. 17676404
26. Sacks DL, Perkins PV, (1984) Identification of an infective stage of Leishmania promastigotes Science 223: 1417–1419. 6701528
27. Melby PC, Yang YZ, Cheng J, Zhao W, (1998) Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 66: 18–27. 9423834
28. Titus RG, Marchand M, Boon T, Louis JA, (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545–555. 3877902
29. Osorio Y, Travi BL, Renslo AR, Peniche AG, Melby PC, (2011) Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. PLoS Negl Trop Dis 5: e962. doi: 10.1371/journal.pntd.0000962 21358812
30. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R, (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24: 167–175. 16465162
31. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67–73. 10838414
32. Engwerda CR, Kaye PM, (2000) Organ-specific immune responses associated with infectious disease. Immunol Today 21: 73–78. 10652464
33. Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, et al. (2011) Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 127: 637–645. doi: 10.1016/j.exppara.2010.12.006 21187086
34. Seifert K, Escobar P, Croft SL, (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65: 508–511. doi: 10.1093/jac/dkp500 20089542
35. Lang T, Goyard S, Lebastard M, Milon G, (2005) Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 7: 383–392. 15679841
36. De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, et al. (2013) Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother 57: 2913–2922. doi: 10.1128/AAC.02398-12 23571538
37. Folgueira C, Quijada L, Soto M, Abanades DR, Alonso C, et al. (2005) The translational efficiencies of the two Leishmania infantum HSP70 mRNAs, differing in their 3'-untranslated regions, are affected by shifts in the temperature of growth through different mechanisms. J Biol Chem 280: 35172–35183. 16105831
38. Pulido SA, Muñoz DL, Restrepo AM, Mesa CV, Alzate JF, et al. (2012) Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Trop 122: 36–45. doi: 10.1016/j.actatropica.2011.11.015 22155571
39. Miβlitz A, Mottram JC, Overath P, Aebischer T, (2000) Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol Biochem Parasitol 107: 251–261. 10779601
40. Mehta SR, Huang R, Yang M, Zhang XQ, Kolli B, et al. (2008) Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery. Clin Vaccine Immunol 15: 1764–1770. doi: 10.1128/CVI.00270-08 18945882
41. Millington OR, Myburgh E, Mottram JC, Alexander J, (2010) Imaging of the host/parasite interplay in cutaneous leishmaniasis. Exp Parasitol 126: 310–317. doi: 10.1016/j.exppara.2010.05.014 20501336
42. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, et al. (2000) Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110: 195–206. 11071276
43. Pescher P, Blisnick T, Bastin P, Späth GF, (2011) Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. Cell Microbiol 13: 978–991. doi: 10.1111/j.1462-5822.2011.01593.x 21501362
44. Croft SL, (1986) In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. Parasitol Today 2: 64–69. 15462773
45. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, et al. (2002) Pharmacokinetics, excretion and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46: 828–833. 11850268
46. Mohamed-Ahmed AH, Seifert K, Yardley V, Burrell-Saward H, Brocchini S, et al. (2013) Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex. Antimicrob Agents Chemother 57: 4608–4614. doi: 10.1128/AAC.02343-12 23796924
47. Bradley DJ, Kirkley J, (1977) Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin Exp Immunol 30: 119–129. 606433